This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
-
Ferric hydroxideis an iron supplement indicated in the treatment and prevention of iron deficiency anemia.
- Generic Name
- Ferric hydroxide
- 博士ugBank Accession Number
- DB13423
- Background
-
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
-
Structure for Ferric hydroxide (DB13423)
- Weight
-
Average: 106.866
Monoisotopic: 106.943155 - Chemical Formula
- FeH3O3
- Synonyms
- Not Available
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
- Not Available
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- 博士ug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
博士ug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Ferric hydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium Phosphate Ferric hydroxide can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium phosphate dihydrate Ferric hydroxide can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Carbidopa Ferric hydroxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy. Cefdinir Ferric hydroxide can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
-
博士ug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Mixture Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FERLOS TABLET, 30 ADET Ferric hydroxide(100 mg)+Icosapent(0.35 mg) Tablet Oral SANTA FARMA İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey 
FERRUM HAUSMANN FORT 100 MG/0,35 MG FİLM TABLET, 30 ADET Ferric hydroxide(100 mg)+Icosapent(0.35 mg) Tablet, film coated Oral ABDİİ伙计İMİLAC圣。TİC。答:Ş。 2020-08-14 Not applicable Turkey
Categories
- ATC Codes
- B03AB04 — Ferric hydroxide
- 博士ug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of inorganic compounds known as transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Transition metal oxoanionic compounds
- Sub Class
- Transition metal hydroxides
- Direct Parent
- Transition metal hydroxides
- Alternative Parents
- Inorganic salts/Inorganic oxides/Inorganic hydrides
- Substituents
- Inorganic hydride/Inorganic oxide/Inorganic salt/Transition metal hydroxide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2UA751211N
- CAS number
- 1309-33-7
- InChI Key
- MSNWSDPPULHLDL-UHFFFAOYSA-K
- InChI
-
InChI=1S/Fe.3H2O/h;3*1H2/q+3;;;/p-3
- IUPAC Name
-
iron(3+) ion trihydroxide
- SMILES
-
[OH-].[OH-].[OH-].[Fe+3]
References
- General References
- Not Available
- External Links
-
- ChemSpider
- 66593
- 1428835
- ChEBI
- 135985
- ChEMBL
- CHEMBL3707285
- Wikipedia
- Iron(III)_oxide-hydroxide
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 4 Recruiting Treatment Iron Deficiency (ID) 1 2 Unknown Status Prevention Breast Cancer 1 Not Available Completed Basic Science Critically Ill Patients 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Injection, solution Oral Solution Oral Solution / drops Oral Tablet Oral Tablet, film coated Oral Solution Oral 100 mg/5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source logP -0.77 ChemAxon pKa (Strongest Acidic) 4.58 ChemAxon Physiological Charge 3 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 0 m3·mol-1 ChemAxon Polarizability 1.78 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available 预测MS / MS谱- 20 v -(注释d) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
博士ug created at June 23, 2017 20:41 / Updated at June 02, 2021 20:04